[S-8 POS] Unity Biotechnology, Inc. SEC Filing
Unity Biotechnology filed Post-Effective Amendment No. 1 to terminate effectiveness of multiple Form S-8 registration statements and remove from registration all unsold shares of its common stock previously registered under those S-8 filings. The filing lists ten Registration Statements spanning 2018–2025 and specifies the originally registered share amounts for various equity plans such as the 2013 Equity Incentive Plan, 2018 Incentive Award Plan, 2020 Inducement Plan and the 2018 Employee Stock Purchase Plan. The Company states the deregistration reflects removal of all unsold securities as of the filing date.
Unity Biotechnology ha depositato l'Emendamento Post-Effective n. 1 per revocare l'efficacia di più dichiarazioni di registrazione sul modulo S-8 e rimuovere dalla registrazione tutte le azioni ordinarie non vendute precedentemente registrate con quei moduli S-8. Il deposito elenca dieci dichiarazioni di registrazione relative al periodo 2018–2025 e indica le quantità di azioni originariamente registrate per diversi piani azionari, come il 2013 Equity Incentive Plan, lo 2018 Incentive Award Plan, il 2020 Inducement Plan e lo 2018 Employee Stock Purchase Plan. La Società dichiara che la deregolamentazione riflette la rimozione di tutti i titoli non venduti alla data del deposito.
Unity Biotechnology presentó la Enmienda Post-Effective Nº 1 para dejar sin efecto múltiples declaraciones de registro en el Formulario S-8 y eliminar de la inscripción todas las acciones ordinarias no vendidas que estaban previamente registradas bajo esas presentaciones S-8. La presentación enumera diez declaraciones de registro que abarcan 2018–2025 y especifica las cantidades de acciones originalmente registradas para diversos planes de capital, como el 2013 Equity Incentive Plan, el 2018 Incentive Award Plan, el 2020 Inducement Plan y el 2018 Employee Stock Purchase Plan. La Compañía indica que la desinscripción refleja la eliminación de todos los valores no vendidos a la fecha de la presentación.
Unity Biotechnology는 다수의 Form S-8 등록명의 효력 종료를 위해 Post-Effective Amendment No. 1을 제출하고, 해당 S-8 제출서에 따라 이전에 등록되었던 모든 미판매 보통주를 등록에서 제외했습니다. 해당 제출서에는 2018년부터 2025년까지의 10개 등록명이 기재되어 있으며, 2013 Equity Incentive Plan, 2018 Incentive Award Plan, 2020 Inducement Plan 및 2018 Employee Stock Purchase Plan과 같은 여러 주식 보상 계획별로 원래 등록된 주식 수가 명시되어 있습니다. 회사는 이번 등록 말소가 제출일 기준 모든 미판매 증권의 제거를 반영한 것이라고 밝혔습니다.
Unity Biotechnology a déposé l'Amendement Post-Effective n° 1 afin de mettre fin à l’effet de plusieurs déclarations d'enregistrement au formulaire S-8 et de retirer de l'enregistrement toutes les actions ordinaires invendues précédemment enregistrées sous ces formulaires S-8. le dépôt énumère dix déclarations d'enregistrement couvrant 2018–2025 et précise les montants d'actions initialement enregistrés pour divers plans d'actions tels que le 2013 Equity Incentive Plan, le 2018 Incentive Award Plan, le 2020 Inducement Plan et le 2018 Employee Stock Purchase Plan. La Société indique que la désinscription reflète la suppression de tous les titres invendus à la date du dépôt.
Unity Biotechnology hat die Post-Effective Amendment Nr. 1 eingereicht, um die Wirksamkeit mehrerer Form S-8-Registrierungserklärungen aufzuheben und alle zuvor unter diesen S-8-Anmeldungen registrierten, unverkauften Stammaktien aus der Registrierung zu entfernen. Die Einreichung listet zehn Registrierungserklärungen aus dem Zeitraum 2018–2025 auf und nennt die ursprünglich registrierten Aktienmengen für verschiedene Aktienpläne wie den 2013 Equity Incentive Plan, den 2018 Incentive Award Plan, den 2020 Inducement Plan und den 2018 Employee Stock Purchase Plan. Das Unternehmen erklärt, dass die Deregistrierung die Entfernung aller unverkauften Wertpapiere zum Zeitpunkt der Einreichung widerspiegelt.
- None.
- None.
Insights
TL;DR Routine deregistration of unsold employee-plan shares; a technical housekeeping filing with limited investor impact.
This Post-Effective Amendment removes unsold shares from ten S-8 registration statements filed between 2018 and 2025. The filing is procedural: it does not report issuance, transfers, or new financings, nor does it change outstanding share counts disclosed elsewhere. For investors, the action typically reduces the number of shares registered for future issuance under those prior filings but does not itself alter the companys cash position, operations, or reported results.
TL;DR Administrative amendment reflecting removal of unsold employee-plan shares; signals no new registrations under these prior S-8s.
The Company has terminated effectiveness for multiple S-8 filings and removed any remaining unsold securities. This is consistent with corporate housekeeping following plan amendments, expirations, or replacement registrations. It may indicate the company prefers consolidating future equity registration under other or newer filings. There is no disclosure here of forfeitures, grants, or material governance events.
Unity Biotechnology ha depositato l'Emendamento Post-Effective n. 1 per revocare l'efficacia di più dichiarazioni di registrazione sul modulo S-8 e rimuovere dalla registrazione tutte le azioni ordinarie non vendute precedentemente registrate con quei moduli S-8. Il deposito elenca dieci dichiarazioni di registrazione relative al periodo 2018–2025 e indica le quantità di azioni originariamente registrate per diversi piani azionari, come il 2013 Equity Incentive Plan, lo 2018 Incentive Award Plan, il 2020 Inducement Plan e lo 2018 Employee Stock Purchase Plan. La Società dichiara che la deregolamentazione riflette la rimozione di tutti i titoli non venduti alla data del deposito.
Unity Biotechnology presentó la Enmienda Post-Effective Nº 1 para dejar sin efecto múltiples declaraciones de registro en el Formulario S-8 y eliminar de la inscripción todas las acciones ordinarias no vendidas que estaban previamente registradas bajo esas presentaciones S-8. La presentación enumera diez declaraciones de registro que abarcan 2018–2025 y especifica las cantidades de acciones originalmente registradas para diversos planes de capital, como el 2013 Equity Incentive Plan, el 2018 Incentive Award Plan, el 2020 Inducement Plan y el 2018 Employee Stock Purchase Plan. La Compañía indica que la desinscripción refleja la eliminación de todos los valores no vendidos a la fecha de la presentación.
Unity Biotechnology는 다수의 Form S-8 등록명의 효력 종료를 위해 Post-Effective Amendment No. 1을 제출하고, 해당 S-8 제출서에 따라 이전에 등록되었던 모든 미판매 보통주를 등록에서 제외했습니다. 해당 제출서에는 2018년부터 2025년까지의 10개 등록명이 기재되어 있으며, 2013 Equity Incentive Plan, 2018 Incentive Award Plan, 2020 Inducement Plan 및 2018 Employee Stock Purchase Plan과 같은 여러 주식 보상 계획별로 원래 등록된 주식 수가 명시되어 있습니다. 회사는 이번 등록 말소가 제출일 기준 모든 미판매 증권의 제거를 반영한 것이라고 밝혔습니다.
Unity Biotechnology a déposé l'Amendement Post-Effective n° 1 afin de mettre fin à l’effet de plusieurs déclarations d'enregistrement au formulaire S-8 et de retirer de l'enregistrement toutes les actions ordinaires invendues précédemment enregistrées sous ces formulaires S-8. le dépôt énumère dix déclarations d'enregistrement couvrant 2018–2025 et précise les montants d'actions initialement enregistrés pour divers plans d'actions tels que le 2013 Equity Incentive Plan, le 2018 Incentive Award Plan, le 2020 Inducement Plan et le 2018 Employee Stock Purchase Plan. La Société indique que la désinscription reflète la suppression de tous les titres invendus à la date du dépôt.
Unity Biotechnology hat die Post-Effective Amendment Nr. 1 eingereicht, um die Wirksamkeit mehrerer Form S-8-Registrierungserklärungen aufzuheben und alle zuvor unter diesen S-8-Anmeldungen registrierten, unverkauften Stammaktien aus der Registrierung zu entfernen. Die Einreichung listet zehn Registrierungserklärungen aus dem Zeitraum 2018–2025 auf und nennt die ursprünglich registrierten Aktienmengen für verschiedene Aktienpläne wie den 2013 Equity Incentive Plan, den 2018 Incentive Award Plan, den 2020 Inducement Plan und den 2018 Employee Stock Purchase Plan. Das Unternehmen erklärt, dass die Deregistrierung die Entfernung aller unverkauften Wertpapiere zum Zeitpunkt der Einreichung widerspiegelt.
FAQ
What did Unity Biotechnology (UBX) file regarding its S-8 registrations?
Which S-8 filings were terminated in this amendment?
How many shares were originally registered under the listed S-8s?
Does this filing indicate issuance of new shares or changes to outstanding shares?
Does the filing affect the companys financial results or cash position?
